Eli Lilly 2011 Annual Report Download - page 52

Download and view the complete annual report

Please find page 52 of the 2011 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 164

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164

FORM 10-K
PERFORMANCE GRAPH
This graph compares the return on Lilly stock with that of the Standard & Poor’s 500 Stock Index and our peer group
for the years 2007 through 2011. The graph assumes that, on December 31, 2006, a person invested $100 each in
Lilly stock, the S&P 500 Stock Index, and the peer group’s common stock. The graph measures total shareholder
return, which takes into account both stock price and dividends. It assumes that dividends paid by a company are
reinvested in that company’s stock.
Value of $100 Invested on Last Business Day of 2006
Comparison of Five-Year Cumulative Total Return Among Lilly, S&P 500 Stock Index, Peer Group1, and Peer Group
(Previous)2
$0.00
$20.00
$40.00
$60.00
$80.00
$100.00
$120.00
Dec-11Dec-09Dec-08Dec-07Dec-06
Peer Group Peer Group (Previous)Lilly
Dec-10
S&P 500
Lilly Peer Group Peer Group
(Previous) S&P 500
Dec-06 $100.00 $100.00 $100.00 $100.00
Dec-07 $105.68 $100.43 $100.12 $105.48
Dec-08 $ 83.08 $ 86.51 $ 85.77 $ 66.52
Dec-09 $ 77.99 $ 96.90 $ 97.75 $ 84.07
Dec-10 $ 80.87 $ 97.81 $ 97.91 $ 96.71
Dec-11 $101.01 $109.47 $112.59 $ 98.76
1We constructed the peer group as the industry index for this graph. It comprises the companies in the
pharmaceutical industry that we used to benchmark the compensation of executive officers for 2011: Abbott
Laboratories; Amgen Inc.; AstraZeneca PLC; Baxter International Inc.; Bristol-Myers Squibb Company;
Genzyme Corporation (prior to the company’s acquisition by Sanofi-Aventis); GlaxoSmithKline plc;
Johnson & Johnson; Merck & Co., Inc.; Novartis AG.; Pfizer Inc.; Sanofi-Aventis; and Takeda
Pharmaceuticals Company.
2Due to changes in the pharmaceutical industry, we revised our peer group for 2011 by adding Baxter
International Inc., Genzyme Corporation (prior to the company’s acquisition by Sanofi-Aventis), and Takeda
Pharmaceuticals Company.
38